Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring.
Ontology highlight
ABSTRACT:
SUBMITTER: Kodimuthali A
PROVIDER: S-EPMC2919267 | BioStudies | 2010-01-01T00:00:00Z
REPOSITORIES: biostudies
Similar Datasets
Project description:Different anion-exchange membranes (AEMs) based on polystyrene (PS)-carrying benzyltrimethyl ammonium cations are currently being developed for use in alkaline fuel cells and water electrolyzers. However, the stability in relation to these state-of-the-art cations needs to be further improved. Here, we introduce highly alkali-stable mono- and spirocyclic piperidine-based cations onto PS by first performing a superacid-mediated Friedel-Crafts alkylation using 2-(piperidine-4-yl)propane-2-ol. This is followed by quaternization of the piperidine rings either using iodomethane to produce N,N-dimethyl piperidinium cations or by cyclo-quaternizations using 1,5-dibromopentane and 1,4-dibromobutane, respectively, to obtain N-spirocyclic quaternary ammonium cations. Thus, it is possible to functionalize up to 27% of the styrene units with piperidine rings and subsequently achieve complete quaternization. The synthetic approach ensures that all of the sensitive ?-hydrogens of the cations are present in ring structures to provide high stability. AEMs based on these polymers show high alkaline stability and less than 5% ionic loss was observed by 1H NMR spectroscopy after 30 days in 2 M aq NaOH at 90 °C. AEMs functionalized with N,N-dimethyl piperidinium cations show higher stability than the ones carrying N-spirocyclic quaternary ammonium. Careful analysis of the latter revealed that the rings formed in the cyclo-quaternization are more prone to degrade via Hofmann elimination than the rings introduced in the Friedel-Crafts reaction. AEMs with an ion-exchange capacity of 1.5 mequiv g-1 reach a hydroxide conductivity of 106 mS cm-1 at 80 °C under fully hydrated conditions. The AEMs are further tuned and improved by blending with polybenzimidazole (PBI). For example, an AEM containing 2 wt % PBI shows reduced water uptake and much improved robustness during handling and reaches 71 mS cm-1 at 80 °C. The study demonstrates that the critical alkaline stability of PS-containing AEMs can be significantly enhanced by replacing the benchmark benzyltrimethyl ammonium cations with N-alicyclic piperidine-based cations.
2020-01-01 | S-EPMC7467773 | BioStudies
Project description:Herein we report the discovery and hit-to-lead optimization of a series of spirocyclic piperidine aldosterone synthase (CYP11B2) inhibitors. Compounds from this series display potent CYP11B2 inhibition, good selectivity versus related CYP enzymes, and lead-like physical and pharmacokinetic properties.
2017-01-01 | S-EPMC5238464 | BioStudies
Project description:A new synthesis of 2-oxa-7-azaspiro[3.5]nonane is described. Spirocyclic oxetanes, including 2-oxa-6-azaspiro[3.3]heptane were converted into o-cycloalkylaminoacetanilides for oxidative cyclizations using Oxone® in formic acid. The expanded spirocyclic oxetane successfully gave the [1,2-a] ring-fused benzimidazole. X-ray crystal structure of the resultant new tetracyclic system, 1',2'-dihydro-4'H-spiro[oxetane-3,3'-pyrido[1,2-a]benzimidazole] and the azetidine ring-opened adduct, N-(2-acetamido-4-bromophenyl)-N-{[3-(chloromethyl) oxetan-3-yl]methyl}acetamide are disclosed.
1000-01-01 | S-EPMC6332447 | BioStudies
Project description:A potent dopamine (D2) receptor agonist (±)-quinagolide, which is used for the treatment of hyperprolactinemia, was synthesized using the ring closing metathesis (RCM) approach from meta-hydroxybenzaldehyde as the starting material. The key features of this synthesis are pyrolytic elimination, late-stage expedient synthesis of functionalized trans-fused tetrahydropyridine-3-carboxylates from olefin 6, via conjugate addition-elimination upon acetate 11, followed by RCM and phenyliodine bis(trifluoroacetate) (PIFA)-mediated Hofmann rearrangement of piperidine-3-carboxamide, which enables the synthesis of 3-aminopiperidine skeleton of quinagolide. For the total synthesis of natural products such as ergot alkaloids, late-stage synthesis of functionalized trans-fused tetrahydropyridine-3-carboxylates using RCM and PIFA-mediated Hofmann rearrangement of piperidine-3-carboxamide, which allows quick access to the synthetically challenging 3-aminopiperidine skeleton, are the main achievements of the present work.
2019-01-01 | S-EPMC6648496 | BioStudies
Project description:INTRODUCTION:Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), approved for the treatment of type 2 diabetes mellitus (T2DM). There currently exists no comparative data to support the use of alogliptin in combination with metformin (met) and sulfonylurea (SU). A decision-focused network meta-analysis (NMA) was performed to compare the relative efficacy and safety of alogliptin 25 mg once daily to other DPP-4 inhibitors as part of a triple therapy regimen for patients inadequately controlled on metformin and SU dual therapy. METHODS:A systematic literature review was conducted to identify published papers of randomized controlled trials (RCTs) that compared alogliptin with other DPP-4 inhibitors (linagliptin, saxagliptin, sitagliptin, and vildagliptin) at their Summary of Product Characteristics (SmPC) recommended daily doses, added on to metformin and SU. Comprehensive comparative analysis involving frequentist meta-analysis and Bayesian NMA compared alogliptin to each DPP-4 inhibitor separately and collectively as a group. Quasi-random effect models were introduced when random effect models could not be estimated. RESULTS:The review identified 2186 articles, and 94 full-text articles were assessed for eligibility. Eight RCTs contained appropriate data for inclusion in the NMA. All analyses over all trial population sets produced very similar results, and show that alogliptin 25 mg is as least as effective (as measured by change in HbA1c from baseline, but supported by other outcome measures: change in body weight and FPG from baseline) and safe (as measured by incidence of hypoglycemia and adverse events leading to study discontinuation) as all the other DPP-4 inhibitors in triple therapy. CONCLUSION:This decision-focused systematic review and NMA demonstrated alogliptin 25 mg daily to have similar efficacy and safety compared to other DPP-4 inhibitors, for the treatment of T2DM in adults inadequately controlled on metformin and SU. (Funded by Takeda Development Centre Americas; EXAMINE ClinicalTrials.gov number, NCT00968708).
2017-01-01 | S-EPMC5380505 | BioStudies
Project description:In the title compound, C17H19N, the piperidine ring adopts a chair conformation. The phenyl rings substituted at the 2- and 6-positions of the piperidine ring subtend dihedral angles of 81.04?(7) and 81.10?(7)° with the best plane of the piperidine ring. The crystal packing features C-H?? inter-actions.
1000-01-01 | S-EPMC3884494 | BioStudies
Project description:A variety of spirocyclic heterocycles have been constructed by a double-alkylation and reductive cyclization approach utilizing ?-heteroatom nitriles as trianion synthons. The method provides access to heteroatom-substituted spirocycles in a variety of ring sizes that are found in natural products and are important in pharmaceutical lead development and optimization.
2013-01-01 | S-EPMC3676279 | BioStudies
Project description:In the title compound, C19H23N, the piperidine ring adopts a chair conformation. The phenyl rings at the 2,6-positions of the piperidine ring occupy equatorial orientations. The crystal structure features C-H?? inter-actions.
1000-01-01 | S-EPMC3884463 | BioStudies
Project description:In the title compound, C19H23N, the piperidine ring has a chair conformation. The phenyl rings are inclined to one another by 52.76?(16)°. One of the methyl substituents on the piperidine ring is axial while the other is equatorial, like the phenyl rings. In the crystal, mol-ecules are linked via C-H?? inter-actions, forming zigzag chains along [001].
1000-01-01 | S-EPMC3998580 | BioStudies
Project description:INTRODUCTION:Although some differences between individual dipeptidyl peptidase-4 (DPP-4) inhibitors may exist, the National Institute for Health and Clinical Excellence (NICE) have recommended that 'prescribers should be encouraged to select the individual DPP-4 inhibitor with the lowest acquisition cost available to them, where all other factors are equal'. We aimed to determine whether or not 'within class' switching to alogliptin, the DPP-4 inhibitor with lowest acquisition cost, is a clinically appropriate strategy. METHODS:This study evaluated people with type 2 diabetes taking DPP-4 inhibitor therapy in addition to at least one other diabetes therapy. Primary care records were reviewed from six clinical commissioning groups (CCGs). For people who had been switched from other DPP-4 inhibitors to alogliptin, an assessment of the impact of switch on both absolute haemoglobin A1c (HbA1c) levels and on HbA1c trajectory was undertaken. Persistence on alogliptin and the need for therapy intensification was also assessed. RESULTS:Overall, 865 people with diabetes met the eligibility criteria for the study. There was no significant difference between pre- and post-switch mean HbA1c level [8.44% (SD 1.52%) vs 8.42% (1.62%), p = 0.6]. Similarly, for patients where there was sufficient data to assess the impact of switching on HbA1c trajectory (n = 319) minimal impact was identified (actual HbA1c at 3 months 8.33% vs projected 8.31%). The majority of people with diabetes (80.76%) remained on alogliptin treatment at 6 months and only 4.54% required additional diabetes therapies. Switching to alogliptin resulted in a median saving of £7.24 per patient-month. CONCLUSION:Switching United Kingdom (UK) primary care patients from other DPP-4 inhibitors to alogliptin did not result in a statistically significant or clinically meaningful change in HbA1c level and few required the addition of further diabetes therapies, suggesting that therapy change or intensification was not considered necessary in most patients who were switched to alogliptin. TRIAL REGISTRATION:ENCePP clinical trial registration number EUPAS29153. FUNDING:Takeda UK Ltd.
2019-01-01 | S-EPMC6612350 | BioStudies